pantoprazole has been researched along with Atrial Fibrillation in 3 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several studies demonstrated that proton pump inhibitors (PPIs) co-administrated with dabigatran in patients with atrial fibrillation (AF) decreased dabigatran trough and peak plasma levels." | 7.96 | The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study. ( Bánovčin, P; Bolek, T; Galajda, P; Hyrdel, R; Kubisz, P; Mokáň, M; Nosáková, L; Samoš, M; Schnierer, M; Škorňová, I; Stasko, J, 2020) |
| " She had been on dabigatran for 13 months due to atrial fibrillation and arterial hypertension." | 7.81 | [Exfoliative esophagitis while taking dabigatran]. ( Meesmann, M; Scheppach, W, 2015) |
| "Several studies demonstrated that proton pump inhibitors (PPIs) co-administrated with dabigatran in patients with atrial fibrillation (AF) decreased dabigatran trough and peak plasma levels." | 3.96 | The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study. ( Bánovčin, P; Bolek, T; Galajda, P; Hyrdel, R; Kubisz, P; Mokáň, M; Nosáková, L; Samoš, M; Schnierer, M; Škorňová, I; Stasko, J, 2020) |
| " She had been on dabigatran for 13 months due to atrial fibrillation and arterial hypertension." | 3.81 | [Exfoliative esophagitis while taking dabigatran]. ( Meesmann, M; Scheppach, W, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Schnierer, M | 2 |
| Samoš, M | 2 |
| Bolek, T | 2 |
| Škorňová, I | 2 |
| Nosáková, L | 1 |
| Bánovčin, P | 2 |
| Galajda, P | 2 |
| Stasko, J | 2 |
| Kubisz, P | 2 |
| Hyrdel, R | 1 |
| Mokáň, M | 2 |
| Lipták, P | 1 |
| Urban, L | 1 |
| Scheppach, W | 1 |
| Meesmann, M | 1 |
3 other studies available for pantoprazole and Atrial Fibrillation
| Article | Year |
|---|---|
The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etexilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedul | 2020 |
Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Interactions; Female; | 2019 |
[Exfoliative esophagitis while taking dabigatran].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Antithrombins; Atrial Fibrillation | 2015 |